Companies/Anika Therapeutics, Inc.

Company profile

Anika Therapeutics, Inc.

NASDAQ: ANIK · Healthcare · Medical - Devices

PublicHQ Bedford, MACIK 0000898437Reports USD

#334 of 1,394 Healthcare companies by revenue34th-percentile growth

EA Score

74B

FH 75DQ 83GM 47SS 80

v0.1 · 65/100 weight · provisional

↑ listing tenure, disclosure history · ↓ 3-yr revenue growth, revenue growth (YoY)

Methodology →

Revenue TTM

$116.3M

Rev growth YoY (TTM)

+23.2%

Net income (FY)

-$10.9M

Employees

288

Market cap

$204.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$112.8M$112.8M2025

Net income-$10.9M-$10.9M2025

Operating income-$11.1M-$11.1M2025

Total assets$190.3M$190.3M2025

Equity$143.5M$143.5M2025

Revenue trend

FY2020 – FY2025 · USD

$30.7M

FY20

$31.7M

FY20

$130.5M

FY20

$147.8M

FY21

$156.2M

FY22

$166.7M

FY23

$119.9M

FY24

$112.8M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Anika Therapeutics, Inc. booked $112.8M in FY2025 revenue, contracting 5.9% year over year — slower than 66% of Healthcare companies we track, at a -9.6% net margin.

Peers · Healthcare

Quanterix Corporation55C InfuSystem Holdings, Inc.80B+Profound Medical Corp.44D KORU Medical Systems, Inc.72B

Key facts

CEOStephen D. Griffin

SectorHealthcare

IndustryMedical - Devices

HeadquartersBedford, MA

ExchangeNASDAQ: ANIK

Employees288

IPO date1993-05-03

Latest filings

8-K2026-06-23 10-Q2026-04-30 8-K2026-04-29 DEF 14A2026-04-28 10-K2026-03-03 8-K2026-02-26 8-K2026-01-08 10-Q2025-11-05

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.